Deutsche Bank raised the firm’s price target on Tenet Healthcare to $150 from $126 and keeps a Buy rating on the shares. The analyst believes taking profits with the shares up 74% year-to-date would be the wrong move at this point. Tenet is in the middle of a multi-year transformation and there could be plenty of equity upside left, the analyst tells investors in a research note. The firm says the company increased guidance solely based on supplemental payments and increased acquisition activity, and not due to outperformance of core operations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet call volume above normal and directionally bullish
- Tenet Healthcare price target raised to $147 from $113 at Barclays
- Tenet Healthcare price target raised to $130 from $120 at Truist
- Tenet Healthcare price target raised to $136 from $109 at RBC Capital
- Tenet Healthcare price target raised to $122 from $95 at Stephens